Nabriva Therapeutics's total inventories for the quarter that ended in Jun. 2023 was $0.00 Mil. Nabriva Therapeutics's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $4.51 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nabriva Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-6.62.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nabriva Therapeutics's Days Inventory for the
three
months ended in Jun. 2023 was 45.39.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nabriva Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 was 2.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nabriva Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 1.75.
Nabriva Therapeutics Total Inventories Historical Data
The historical data trend for Nabriva Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nabriva Therapeutics Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Nabriva Therapeutics (OTCPK:NBRVF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Nabriva Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nabriva Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Nabriva Therapeutics Total Inventories Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 